Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions

Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions

Background: IgPro20 is the first approved subcutaneous immunoglobulin (SCIg) preparation for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Two different doses of the SCIg preparation were investigated in the pivotal PATH study. Real-world data, and particul...

Full description

Bibliographic Details
Main Authors: Stefan Gingele, Moritz Koch, Anna Christina Saparilla, Gudrun M. Körner, Jarle von Hörsten, Marina Gingele, Tabea Seeliger, Franz Felix Konen, Martin W. Hümmert, Alexandra Neyazi, Martin Stangel, Thomas Skripuletz
Format: Article
Language:English
Published: SAGE Publishing 2021-04-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/17562864211009100

Internet

https://doi.org/10.1177/17562864211009100

Similar Items